Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib trial of aldoxorubicin plus gemcitabine in patients with relapsed ovarian cancer

Next Previous
Search
Trial Profile

Phase Ib trial of aldoxorubicin plus gemcitabine in patients with relapsed ovarian cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldoxorubicin (Primary) ; Gemcitabine
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors LadRx Corporation

    • Most Recent Events

    • 18 Nov 2014 New trial record
    • 29 Sep 2014 The FDA has granted aldoxorubicin Orphan Drug Designation for ovarian cancer, and this phase Ib trial is planned, according to a CytRx Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top